Literature DB >> 26322872

Role of efflux pumps inhibitor in decreasing antibiotic resistance of Klebsiella pneumoniae in a tertiary hospital in North India.

Joel Filgona1, Tuhina Banerjee, Shampa Anupurba.   

Abstract

INTRODUCTION: The contribution of efflux systems to drug resistance in Enterobacteriaceae is becoming increasingly appreciated. This study phenotypically analyzed the role of efflux mechanisms in resistance to ertapenem, doripenem, and tigecycline among clinical isolates of carbapenem-resistant Klebsiella pneumoniae (CRKP).
METHODOLOGY: Multidrug-resistant and carbapenem non-susceptible K. pneumoniae isolates were determined by disk diffusion test. Further susceptibility of these isolates to carbapenems, ceftriaxone, cefoperazone, ceftazidime, tigecycline, and colistin was determined by agar dilution assay, and CRKP was identified. While modified Hodge test was used to confirm carbapenemase production, the contribution of efflux mechanisms was determined by a minimum inhibitory concentration (MIC) reduction assay, and typing was done by enterobacterial repetitive intergenic consensus (ERIC) polymerase chain reaction (PCR).
RESULTS: Of the 238 isolates of K. pneumoniae, 174 were multidrug resistant and 74 were CRKP. Forty of the CRKP were positive for carbapenemase production, while 43, 11, and 2 of the CRKP isolates had elevated MIC of ≥ 32 µg/mL for ertapenem, doripenem, and tigecycline, respectively. Twofold or higher MIC reduction to ertapenem, doripenem, and tigecycline was observed in 6, 28, and 27 isolates, respectively; however, non-susceptibility to ertapenem, doripenem and tigecycline was abolished in 2, 11, and 18 K. pneumoniae isolates, respectively. Nine clones of CRKP widely distributed within the hospital were obtained from ERIC PCR.
CONCLUSIONS: Although colistin retained better activity against CRKP, efflux pumps contributed to increased MIC in ertapenem, doripenem, and tigecycline. Therefore, efflux systems are important aspects that should be explored in the fight against multidrug-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26322872     DOI: 10.3855/jidc.6216

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  Detection of synergistic antimicrobial resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from post-operative wound infections.

Authors:  Asad Bashir Awan; Aixin Yan; Yasra Sarwar; Peter Schierack; Aamir Ali
Journal:  Appl Microbiol Biotechnol       Date:  2021-11-19       Impact factor: 4.813

2.  Panel strain of Klebsiella pneumoniae for beta-lactam antibiotic evaluation: their phenotypic and genotypic characterization.

Authors:  Roshan Dsouza; Naina Adren Pinto; InSik Hwang; YoungLag Cho; Dongeun Yong; Jongrak Choi; Kyungwon Lee; Yunsop Chong
Journal:  PeerJ       Date:  2017-01-19       Impact factor: 2.984

Review 3.  Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae.

Authors:  Rebekah M Martin; Michael A Bachman
Journal:  Front Cell Infect Microbiol       Date:  2018-01-22       Impact factor: 5.293

4.  Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.

Authors:  Raspail Carrel Founou; Luria Leslie Founou; Mushal Allam; Arshad Ismail; Sabiha Yusuf Essack
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

5.  A Polyclonal Spread Emerged: Characteristics of Carbapenem-Resistant Klebsiella pneumoniae Isolates from the Intensive Care Unit in a Chinese Tertiary Hospital.

Authors:  Zhengzheng Wang; Fangyou Yu; Xiaofei Shen; Meilan Li
Journal:  Pol J Microbiol       Date:  2020-09-08

6.  Lavender essential oil induces oxidative stress which modifies the bacterial membrane permeability of carbapenemase producing Klebsiella pneumoniae.

Authors:  Shun-Kai Yang; Khatijah Yusoff; Warren Thomas; Riaz Akseer; Maryam Sultan Alhosani; Aisha Abushelaibi; Swee-Hua-Erin Lim; Kok-Song Lai
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.